期刊文献+

利奈唑胺与万古霉素对小鼠耐甲氧西林金黄色葡萄球菌血流感染的疗效评估 被引量:3

Efficacy of linezolid versus vancomycin in an a bacteriemia model in mice infected by methicillin-resistant staphylococcus aureus
下载PDF
导出
摘要 目的利用临床分离株耐甲氧西林金黄色葡萄球菌(MRSA)菌株感染BALB/c小鼠,建立小鼠的血流感染模型,再用该模型比较利奈唑胺与万古霉素对感染小鼠的治疗效果。方法分别对MRSA感染组、利奈唑胺治疗组和万古霉素治疗组小鼠的临床症状、生存时间曲线和血液中的细菌计数进行时相性的观察和检测。结果 MRSA感染组小鼠的生存率明显低于利奈唑胺治疗组和万古霉素治疗组,且利奈唑胺治疗组要高于万古霉素治疗组,但二者之间差异无统计学意义。另外,MRSA感染组小鼠血液中的菌量较高,而在利奈唑胺治疗组或万古霉素治疗组血液中的菌量明显减少,但二者之间差异无统计学意义(P>0.05)。结论利奈唑胺和万古霉素治疗小鼠MRSA血流感染的疗效基本相当。 Objective To established a bacteriemia model of BALB/c mice after infection with clinical methicillin-resistant staph-ylococcus aureus(MRSA) strain and then evaluated by linearly versus vancomycin in the treatment of MRSA experimental bacterae-mia. Methods We monitored the clinical signs, gross observations of MRSA infected mice,vancomycimtreated mice and linezolid-treated mice and counted the bacteria in blood among different groups. Results The survival rate in MRSA infected group was sig- nificantly lower than that in vancomycin-treated group or linezolid-treated group. The survival rate in linezolid-treated group was higher than that in vancomycin-treated group, however, there was no significant difference between them. Otherwise, bacterial blood concentrations was higher in MRSA infected group,but there was no significant difference between linezolid-treated group and van-comycin-treated group. Conclusion The efficacy of linezolid versus vaneomycin regimens against the MRSA isolate is not statisti-cally different,although both treatments are significantly different from MRSA infected group.
出处 《重庆医学》 CAS CSCD 北大核心 2013年第16期1844-1845,1848,共3页 Chongqing medicine
关键词 甲氧西林抗药性 葡萄球菌 金黄色 血流感染 利奈唑胺 万古霉素 模型 动物 methicillin resistant staphylococcus aureus bacteraemia linezolid vancomycin models, animal
  • 相关文献

参考文献14

  • 1Gnmdmann H, Aires-de-Soma M, Boyce J, et al. Emer- gence and resurgence of methicillin-resistant Staphylococ- cus aureus as a public health threat[J]. Lancet, 2006,36 (8) :874-885.
  • 2Daum Rs, Seal JB. Evolving antimicrohial chemotherapy for Staphylococcus aureus infections: Our backs to the wall[J]. Crit Care Meal,2001,29(1) :92-96.
  • 3Otter J A, French GL. Nosocomial transmission of community- associated methicillin-resistant Staphylococcus aureus., all e- merging threat[J]. Lancet Infect Dis, 2006,12 (6) : 753-755.
  • 4Chang S, Sievert DM, Hageman JC, et al. Infection with van- comycin resistant Staphylococcus aureus containing vanA re- sistance gene[J]. N Engl J Med, 2003,348(14) : 1342-1344.
  • 5Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid : an oxazolidinone antimicrobial agent [J]. Clin Therapeutics, 2001,23 (3) : 356-391.
  • 6Kaplan SL,Patterson L,Edwards KM,et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children[J]. Pediatr Infect Dis J, 2001,20 (3) : 488-494.
  • 7Shorr AF,Kunkel MJ,Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: Pooled analysis of randomized studies[J]. J Antimicrobial Chemother,2005,56(5) :923-929.
  • 8Voyieh JM, Bmughton KR, Sturdevant DE, et al. Insights into mechanisms used by Staphylococcus aureus tO avoid destruction by human neutrophils[J]. J Immunol, 2005, 175(6) : 3907-3919.
  • 9王德成,王星,周文江,彭秀华,高谦.耐甲氧西林金黄葡萄球菌小鼠菌血症感染模型的建立与评估[J].中华微生物学和免疫学杂志,2010,30(7):603-607. 被引量:4
  • 10Faria NA,Oliveim D, Westh H, et al. Epidemiology of e- merging methicillin-resistant Staphylococcus aureus(MR- SA) in Denmark: a nationwide study in a country with low prevalence of MRSA infection[J]. J Clin Microbiol, 2005,43(14) : 1836-1842.

二级参考文献41

  • 1吴跃平,章文,陈运生,徐刚,陈月生.儿童血培养病原菌分布及耐药性分析[J].中华医院感染学杂志,2006,16(4):463-465. 被引量:35
  • 2朱德妹,汪复,张婴元.2005年上海地区细菌耐药性监测[J].中国感染与化疗杂志,2006,6(6):371-376. 被引量:82
  • 3褚云卓,年华,邓宇欣,欧阳金鸣,王倩.血培养的菌谱调查及耐药性分析[J].中华医院感染学杂志,2007,17(4):472-474. 被引量:50
  • 4Grundmann H,Aires-de-Sousa M,Boyce J,et al.Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a publichealth threat.Lancet,2006,368(9538):874-885.
  • 5Daum RS,Seal JB.Evolving antimicrobial chemotherapy for Staphylococcus aureus infections:Our backs to the wall.Crit Care Med,2001,29(4 Suppl):N92-96.
  • 6Maltezou HC,Giamarellou H.Community-acquired methicillin-resistant Staphylococcus aureus infections.Int J Antimicrob Agents,2006,27(2):87-96.
  • 7Otter JA,French GL.Nosocomial transmission of community-associated methicillin-resistant Staphylococcus aureus:an emerging threat.Lancet Infect Dis,2006,6(12):753-755.
  • 8Goldstein EJ,Citron DM,Warren YA,et al.Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and susceptible S.aureus.J Med Microbiol,2008,57 (Pt 4):452-456.
  • 9Adedeji A,Gray JW.MRSA at an English children's hospital from 1998 to 2003.Arch Dis Child,2005,90(7):720-723.
  • 10Faria NA,Oliveira DC,Westh H,et al.Epidemiology of emerging methicillin-resistant Staphylococcus aureus (MRSA) in Denmark:a nationwide study in a country with low prevalence of MRSA infection.J Clin Microbiol,2005,43(4):1836-1842.

共引文献149

同被引文献23

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部